Work Area: IP public policy

Latest content

The European Commission’s SEP licensing plans are terrible on every level

Reported DG Grow proposals designed to make FRAND dealmaking in Europe more transparent, predictable and efficient are one-sided and poorly thought-through, so will do much more harm than good

30 March 2023

European Commission to propose radical new SEP/FRAND regime with major consequences for patent owners

Draft EU rules are set to empower EUIPO with mandatory essentiality checking framework but kickback expected

29 March 2023

Countdown to IPBC Korea 2023

Just one month until IP leaders will gather in  Seoul for an agenda tackling policy developments, market trends, and commercial pressures

20 March 2023

We need a better debate about US pharma patents

Opinion: Popular attacks on America’s life sciences patent system are highly misleading

18 March 2023

Five things to watch in US Supreme Court oral argument in Amgen v Sanofi

Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112

15 March 2023

Senate IP subcommittee appointments inspire cautious optimism for patent owners

Senators Chris Coons and Thom Tillis – both pro-patentee – take the lead but it doesn’t mean bills will pass

14 March 2023

OpenSky: ending another round of IPR abuse whack-a-mole

Saturday Opinion: USPTO Director Kathi Vidal’s sanctions are a good start, but more must be done to curb untoward behaviour going forward

11 March 2023

EPO staff endorse industry patent quality complaints

Response to IPQC continues a long-running and bitter feud between leadership and staff

10 March 2023

A roadmap for industry-academia collaboration to advance IP policy

Ethical and transparent partnerships can help resolve pressing issues all while furthering a company’s goals and interests

08 March 2023

US commenters warn of ‘unintended consequences’ in pharma patent crackdown

Potential initiatives to limit continuation practice are causing deep divides in the life sciences patent community – causing technology licensors and Big Tech to take sides

07 March 2023

Unlock unlimited access to all IAM content